You say you want a Revolution? Oncology company is latest to post big gain after IPO

Revolution’s first day performance suggests appetite for new biotech listings continues unabated in 2020, as investors’ demand for the cancer company’s shares rose both before and after its offering priced.

Revolution Medicines Inc. (NASDAQ:RVMD) raised $238 million through the sale of 14 million shares at $17, giving it a postmoney valuation of $967.3 million. By the end of Thursday’s session, when shares climbed $11.90 (70%) to $28.90, its value had risen to $1.6 billion...